Quantcast

Latest Telik Inc. Stories

2011-06-07 15:05:00

PALO ALTO, Calif., June 7, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced the initiation of a Phase 2 clinical trial to evaluate oral Telintra in patients with Revlimid refractory or resistant, deletion 5q myelodysplastic syndrome (del 5q MDS). This is a multicenter trial intended to enroll up to 117 evaluable patients. It employs a sequential design with two interim analyses. These patients are transfusion dependent with Low to Intermediate-1 Risk MDS. Telintra will be...

2011-05-16 15:05:00

PALO ALTO, Calif., May 16, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported financial results for the first quarter ended March 31, 2011. The net loss for the quarter ended March 31, 2011 was $3.7 million, or $0.07 per share, compared with a net loss of $5.3 million, or $0.10 per share, for the same period in 2010. Total research and development expenses (R&D) in the first quarter of 2011 were $1.7 million, compared to $2.8 million for the same period in 2010. The...

2011-04-05 07:00:00

PALO ALTO, Calif., April 5, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today presented data at the 102nd American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida on a group of second generation analogs of ezatiostat, the most clinically advanced product in development at Telik. Ezatiostat is the first inhibitor of glutathione-S-transferase P1-1 (GST P-1), a validated enzyme target in Myelodysplastic Syndrome (MDS), to successfully complete a Phase 2 clinical...

2011-03-30 15:05:00

PALO ALTO, Calif., March 30, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced that CEO Michael M. Wick, M.D., Ph.D. will provide a corporate overview at the 10th Annual Needham Healthcare Conference in New York City on Wednesday, April 6 at 11:20 a.m. Eastern time (8:20 a.m. Pacific time), in the New York Palace Hotel's Henry's Suite. A live and archived webcast of the presentation will be available on the Telik website, www.telik.com. The archived broadcast of the...

2011-03-25 18:31:00

PALO ALTO, Calif., March 25, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced that a presentation titled: "Synthesis and biochemical characterization of novel analogues of ezatiostat hydrochloride (TLK199, Telintra®)" will be given at the 102nd annual meeting of the American Association for Cancer Research (AACR) in Orlando, Florida. The presentation will be made on Tuesday, April 5th, 2011 from 8:00 am - 12:00 pm in Exhibit Hall A4-C, Poster Section; Cancer...

2011-02-22 15:30:00

PALO ALTO, Calif., Feb. 22, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) reported a net loss of $9.8 million, or $0.18 per share, for the three months ended December 31, 2010, compared with a net loss of $4.2 million, or $0.08 per share, for the comparable period in 2009. For the year ended December 31, 2010, net loss was $24.7 million, or $0.46 per share, compared with a net loss of $23.7 million, or $0.44 per share, for the year ended December 31, 2009. For the quarter ended December...

2011-02-09 03:25:00

PALO ALTO, Calif., Feb. 9, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced that CEO Michael M. Wick, M.D., Ph.D. will provide a corporate overview at the 13th Annual BIO CEO & Investor Conference in New York City on Tuesday, February 15 at 3:00 p.m. Eastern time (12:00 p.m. Pacific time), in the Waldorf-Astoria Hotel's Conrad Suite. A live and archived webcast of the presentation will be available on the Telik website, www.telik.com. The archived broadcast of the...

2010-11-10 13:44:00

PALO ALTO, Calif., Nov. 10, 2010 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today it will report data from the Phase 2 randomized multicenter study of Telintra® (ezatiostat HCl) tablets in the treatment of patients with Myelodysplastic Syndrome at the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL. Details of the presentation are as follows: Abstract #2910 -Myelodysplastic Syndromes: Poster II; Sunday, December 5,...

2010-11-03 15:05:00

PALO ALTO, Calif., Nov. 3, 2010 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $4.7 million, or $0.09 per share, for the third quarter ended September 30, 2010, compared with a net loss of $6.1 million, or $0.11 per share, for the comparable period in 2009. For the quarter ended September 30, 2010, total operating costs and expenses were $4.7 million, compared with $6.2 million in the 2009 third quarter. Operating expenses in the 2010 third quarter...

2010-11-02 18:27:00

PALO ALTO, Calif., Nov. 2, 2010 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) a clinical stage drug development company focused on developing drugs to treat cancer, announced that it has been awarded grants totaling $1,222,396 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP). The grants are intended to advance five of Telik's ongoing therapeutic drug development programs including the company's most advanced investigational drug candidate,...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related